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Background: Low back pain is a common and disabling condition leading to large health service and societal
costs. Although there are several treatment options for back pain little is known about how to improve patient
choice in treatment selection. The purpose of this study was to pilot a decision support package to help people
choose between low back pain treatments.
Methods: This was a single-centred pilot cluster randomised controlled trial conducted in a community physiotherapy
service. We included adults with non-specific low back pain referred for physiotherapy. Intervention participants were
sent an information booklet prior to their first consultation. Intervention physiotherapists were trained to enhance their
skills in shared informed decision making. Those in the control arm received care as usual. The primary outcome was
satisfaction with the treatment received at four months using a five-point Likert Scale dichotomised into “satisfaction”
(very satisfied or somewhat satisfied) and “non-satisfaction” (neither satisfied nor dissatisfied, somewhat dissatisfied or
very dissatisfied).
Results: We recruited 148 participants. In the control arm 67% of participants were satisfied with their treatment and
in the intervention arm 53%. The adjusted relative risk of being satisfied was 1.28 (95% confidence interval 0.79 to 2.09).
For most secondary outcomes the trend was towards worse outcomes in the intervention group. For one measure;
the Roland Morris Disability Questionnaire, this difference was clinically important (2.27, 95% confidence interval 0.08 to
4.47). Mean healthcare costs were slightly lower (£38 saving per patient) within the intervention arm but health
outcomes were also less favourable (0.02 fewer QALYs); the estimated probability that the intervention would be
cost-effective at an incremental threshold of £20,000 per QALY was 16%.
Conclusion: We did not find that this decision support package improved satisfaction with treatment; it may have
had a substantial negative effect on clinical outcome, and is very unlikely to prove cost-effective. That a decision
support package might have a clinically important detrimental effect is of concern. To our knowledge this has not been
observed previously. Decision support packages should be formally tested for clinical and cost-effectiveness, and safety
before implementation.
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A patient centred model of health care is an explicit ambi-
tion of a number of established health care providers inter-
nationally including the UK National Health Service (NHS)
[1]. The NHS is making a substantial investment in pro-
moting shared decision making across a wide range of
disorders through the ‘Right Care’ programme [2]. Shared
informed decision making is one important part of the
patient-centred model of care. To encourage and imple-
ment informed shared decision making, decision aids for
patients have been developed to support treatment choice
in many areas including breast cancer [3,4], hypertension
[5] and hormonal replacement therapy [6]. These patient
decision aids provide information, evidence and guidance
to help patients make decisions where there is some choice
and where the decision may be influenced by the patient’s
values. Randomised controlled trials investigating the
effectiveness of patient decision aids have shown positive
effects on patient satisfaction with the decision-making
process, enhanced knowledge acquisition and less deci-
sional conflict or anxiety when making their decision on
treatment preference [7-10]. In contrast, few trials have
tested the effect of patient decision aids on clinical out-
comes and overall these findings are not conclusive [11,12].
The few trials that report cost outcomes provide insuffi-
cient evidence to conclude that these interventions are cost
saving; none report a cost-effectiveness analysis [13].
Low back pain is a common condition, which is asso-
ciated with major occupational and healthcare costs
[14-17] often leading to many years lost to disability
[18]. In 2009, the National Institute for Health and Care
Excellence (NICE) published guidance on the manage-
ment of low back pain for those suffering with the con-
dition from six weeks to one year. These guidelines
recommend that people with persistent low back pain
should be offered a choice of three core treatments:
manual therapy, acupuncture, or supervised group exer-
cise [19]. The guidelines also emphasise the need for cli-
nicians to take into account the individual’s needs and
preferences as part of patient-centred care [1,16].
Patients want more information about the available
treatment options for their back pain to enable them to
make better informed decisions [20-28]. Clinicians should
therefore adopt a collaborative and shared approach to
decision-making. This suggests a need for greater involve-
ment by the patient in choosing the treatment they would
most prefer, after a discussion with their health profes-
sional during which they have received factual information
about different available options [29,30]. The practical ap-
plication and evaluation of informed shared decision mak-
ing in the non-surgical treatment of low back pain has,
however, been limited.
In this pilot cluster randomised controlled trial (RCT)
we tested the hypothesis that the use of a decision aidtogether with an informed shared decision-making con-
sultation approach would improve satisfaction with treat-
ment for patients referred to a community physiotherapy
service for treatment of low back pain. A positive signal
within this pilot study would justify proceeding to a full
trial to test its clinical and cost-effectiveness.
Methods
Trial design
The study protocol and the intervention are described
in detail elsewhere [31,32]. They are briefly summarised
here. In our original study design we planned to ran-
domise participants individually to treatment arms.
Changes in the organisation of the appointment service
around the time recruitment started meant we were
unable to do this. We therefore, with agreement from
the funder, changed to a cluster randomised design.
Ethical approval was granted by Warwickshire REC
(10/H1211/2).
Participants
We recruited participants aged 18 or over who had been
referred to a single community physiotherapy depart-
ment in Coventry for treatment of non-specific low
back pain. All participants needed to be fluent in
English. We excluded participants with severe psychi-
atric or personality disorders, a terminal or critical
illness and those with possible serious spinal pathology
(e.g. tumour, sepsis or fracture).
Interventions
Our intervention package was developed after explora-
tory work including literature reviews, a Delphi study, a
nominal group with physiotherapists, focus groups with
patients’ and secondary analysis of existing interview
data. We have described this process in detail elsewhere
[32]. We developed a patient decision support package
in the form of a booklet and associated training for the
physiotherapists [32] (Additional file 1). The physiotherap-
ist training was a two-hour session to enable the therapists
to develop an understanding of how to incorporate the de-
cision support package within their patient-centred con-
sultations, facilitate patient involvement as well as
providing appropriate information by recognising and
responding to patient concerns.
The intervention consisted of a patient booklet that
details the available treatment options which include ex-
ercise, manual therapy, acupuncture, and a cognitive be-
havioural approach. The booklet also provided answers
to the frequently asked questions associated with each
option. Space was provided in the booklet to enable pa-
tients to note if they felt they had sufficient information
and any points they wanted to discuss in the consult-
ation. This was posted ahead of the participant’s first
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they attended.
Those allocated to a therapist in the usual care arm
attended their appointment without any prior treatment
information and with a therapist not trained on in-
formed shared decision making.
Procedure
Once a general practitioner referral was received, pa-
tients were given an appointment by a booking clerk
who was blind to the physiotherapists’ allocation. These
patients were then sent an invitation to join the study.
Each invitation pack contained an invitation letter, pa-
tient information sheet, consent form, baseline question-
naire and reply slip. The invitation advised participants
that the trial was looking at whether giving physiothera-
pists additional training will improve their satisfaction
with their choice of back pain treatments. Participants
were advised that they would be randomly assigned to
either a specially trained physiotherapist or a physiother-
apist who had not had the additional training. Potential
participants returned the consent form and completed
baseline questionnaire to the research team at Warwick
Clinical Trials Unit. Those who met the inclusion cri-
teria, completed the baseline questionnaire and con-
sented to the trial were included.
Once the baseline questionnaire was received those par-
ticipants allocated to a therapist in the intervention arm of
the study were sent a copy of the decision support booklet
by post from the physiotherapy department; typically
around two weeks prior to their first consultation [32].
Participants were then expected to attend their appoint-
ment as usual. Those allocated to a therapist in the usual
care arm attended their appointment as usual.
Outcomes
The primary outcome measure was satisfaction with treat-
ment at four months using a five-point Likert Scale (very
satisfied to very dissatisfied) dichotomised into “satisfaction”
(very satisfied or somewhat satisfied) and “non-satisfaction”
(neither satisfied nor dissatisfied, somewhat dissatisfied or
very dissatisfied).
Participants were sent a satisfaction with decision scale
[33] to complete soon after the planned initial consult-
ation. Other secondary outcome measures collected at
four months were the Roland Morris Disability Ques-
tionnaire [34], modified Von Korff pain and disability
scales [35], SF-12 [36], EQ-5D [37], hospital anxiety and
depression scale [38], pain self-efficacy questionnaire
[39], and the fear avoidance beliefs questionnaire [40].
Outcome measures were collected at baseline and four
months after entering the trial by which time we would
expect all treatment to have been completed and any posi-
tive effects maximised. In addition we sent an immediatefollow-up questionnaire looking at satisfaction with deci-
sion soon after the date of their first appointment. We
sent two postal reminders; if necessary this was followed
by a phone call from the study team member, who was
blind to treatment allocation, to collect the primary out-
come and modified Von Korff scales [35].
Sample size
To show an improvement of 25% in satisfaction with
treatment from 50% in the control arm at the 5% signifi-
cance level with 80% power requires data on 116 sub-
jects. Although such satisfaction measures are prone to
ceiling effect we have used a dichotomised scale. Allow-
ing for 20% loss to follow-up we originally aimed to re-
cruit 150 subjects. With the change in design (from
individual randomised to cluster randomised trial) we
needed to account for clustering effects. We did a
blinded interim sample size review [41] after we had re-
cruited 41 participants to estimate the intra-cluster cor-
relation coefficient (ICC) to allow a re-calculation of
sample size. The estimated ICC was close to zero and
there were 14 clusters with size ranges from one to six.
Thus, the revised sample size was based on 14 clusters
with an average cluster size of nine and assuming, con-
servatively, an ICC of 0.01, a 5% significance level and
80% power, and allowing a 20% of loss to follow-up, the
total sample size needed was 158.
Randomisation
Using stratified block randomisation all physiothera-
pists working in the service were randomised to deliver
either the usual care or the decision support package
intervention in a 1:1 ratio, stratified by their number of
years of experience (≤6 vs. > 6 years since their qualifi-
cation) and the amount of time they worked for the ser-
vice each week. The randomisation was set up by an
independent statistician. Members of the team were
blind to the allocation of participants to physiothera-
pists. Practical constraints meant that we were unable
to train and randomise any new physiotherapists join-
ing the service after the trial had started. Participants
consulting the newly started physiotherapists were all
assigned to control.
Statistical methods
The statistical team (SWH, TF) developed a statistical ana-
lysis plan that was agreed by the study team prior to a
database freeze and unblinding of the data. The main
summary and analysis were intention to treat. Continuous
variables at baseline and follow-ups were summarised as
mean, standard deviation, median and interquartile range.
Categorical variables were summarised as frequency
and percentage. The primary outcome, satisfaction with
treatment, was dichotomised into “satisfaction” and “non-
Table 1 Physiotherapists and patients by treatment arms
and physiotherapists’ years of experience
Treatment arms







No. of patients 38 23 10
Median 12 6 1






No. of patients 30 10 8
Median 8.5 10 1
(min, max) (2, 11) (10, 10) (1, 5)
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change from baseline. The ICC and its confidence interval
for the primary outcome was also summarised [42].
Dichotomous outcomes were modelled with generalised
linear mixed effects regression with logit link and continu-
ous outcomes were analysed using Gaussian linear mixed
effects models. For ease of interpretation results were
transformed from the odds ratio to the relative risk scale.
The estimation was obtained in the same manner as for
odds ratio but with log link. The study arm, physiothera-
pists’ years of experience (≤6 vs. >6 years) and the pain se-
verity (modified Von Korff pain score measured at
baseline) formed the fixed effects whilst the physiothera-
pists (clusters) formed the random effects. In a sensitivity
analysis physiotherapists recruited post-randomisation
were excluded. All statistical analyses were two-sided and
point estimates were reported with the corresponding
95% confidence interval.
Cost-effectiveness analysis was conducted in line with
the NICE reference case [43] and International Society
for Pharmacoeconomics and Outcome Research recom-
mendations [44]. We estimated the total cost of back
pain related NHS care over four months. Costs for the
decision support package included printing and delivery
of the package to patients, and training for physiothera-
pists. Participants’ use of other NHS services for back
pain was obtained from the follow-up questionnaire and
physiotherapy records. Unit costs for health services
were identified from standard national sources. The ef-
fectiveness of the decision support package and usual
care were measured using quality adjusted life years
(QALYs), estimated using the ‘area under the curve’ ap-
proach from EQ-5D data.
Missing resource use and utility data were imputed
and integrated in the cost-effectiveness analysis using
multiple imputation methods. The Stata Multivariate
Imputation using Chained Equations (MICE) procedure
was used to estimate missing resource use and EQ-5D
observations based on patients’ age, gender, baseline
RMDQ score and treatment group. Between-group dif-
ferences in mean costs and QALYs were estimated using
bootstrap regression of the imputed datasets. The seem-
ingly unrelated regression method [45] was used to
simultaneously estimate differences of costs and QALYs
between treatment arms, adjusting for patient age,
sex, Roland Morris Disability Questionnaire and EQ-5D
scores at baseline, and physiotherapist experience. A
simple model was used to extrapolate between-group
differences in QALYs and costs (excluding the cost of
the decision support package itself ) at the end of the
trial to a maximum of one year from baseline. This was
based on the results of a published meta-analysis of low
back pain trial data [46]. Analyses were done in SAS 9.3
and Stata 11.0.Results
A total of 19 physiotherapists were involved in the trial.
Twelve physiotherapists were present at the start of the
trial, and seven were randomised to the decision support
arm. Of the seven physiotherapists in the intervention
arm, four had more than six years of experience,
whereas of the five who were randomised to the control
arm only one of them had more than six years of experi-
ence (Table 1). The other seven physiotherapists who
joined the department after randomisation were allo-
cated to the control arm and four of them had more
than six years of experience.
We approached 238 people to take part in the trial;
148 (62%) joined the study. The baseline characteristics
of the two groups were similar (Table 2). Eighty-five
(57%) participants were assigned to the decision support
arm. We obtained four–month follow-up data on 119
(80%) of our participants (Figure 1). Of these 114 had
complete data for both primary endpoint and baseline
data for analysis. The adjusted percentage satisfied with
their treatment in the intervention arm was 53% (n = 33/63)
and in the control arm it was 67% (n = 34/51). The adjusted
odds ratio was 1.85 (95% confidence interval 0.65 to 5.25:
the estimated ICC was 0.018; −0.11 to 0.15). Correspond-
ingly, the adjusted relative risk was 1.28 (0.79 to 2.09). We
infer that the rate of satisfied with treatments in the control
arm was between 0.79 and 2.09 times that for those in the
intervention arm.
For all but one of our secondary outcomes the point
estimate for the difference favours the control interven-
tion. The exception is the SF-12 mental component
scores (Table 3, Figure 2). For the Roland Morris Dis-
ability Questionnaire the difference between treatment
arms was −2.27 (−4.47 to −0.08).
The responses to the satisfaction with decision question-
naire were dichotomised to “agreement” and “non-agree-
ment.” A total of 103 participants returned the immediate
Table 2 Demographic and clinical characteristics of respondents at baseline
Decision support package Usual care
n (%) n (%)
No. of participants 85 (57.4) 63 (42.6)
Age, years
Mean (SD) 46.9 (13.8) 48.8 (16.7)
Median (IQR) 47.6 (36.1, 56.9) 46.8 (33.5, 63.4)
Sex:
Male 28 (32.9) 22 (34.9)
Female 57 (67.1) 41 (65.1)
Ethnicity:
White 71 (83.5) 56 (88.9)
Mixed 3 (3.5) 2 (3.2)
Asian or Asian British 7 (8.2) 3 (4.8)
Black or Black British 3 (3.5) 2 (3.2)
Chinese 1 (1.2) 0 (0.0)
Currently working:
Yes 45 (52.9) 35 (55.6)
No: 40 (47.1) 28 (44.4)
Retired 13 (31.7) 14 (46.7)
Stay at home 4 (9.8) 3 (10.0)
Unable to work due to low back pain 8 (19.5) 8 (26.7)
Unable to work due to other illness 6 (14.6) 2 (6.7)
Unemployed and looking for work 3 (7.3) 1 (3.3)
In full time education 2 (4.9) 0 (0.0)
Others 5 (12.2) 2 (6.7)
Hours of paid work per week:
No. of participants 49 38
Mean (SD) 31.8 (12.6) 30.2 (12.4)
Median (IQR) 37 (25, 40) 35 (21, 39)
Pain in lower back pain in the last four weeks:
Yes 85 (100.0) 63 (100.0)
If Yes:
Pain limit usual activities for more than one day:
Yes 70 (84.3) 54 (85.7)
No 13 (15.7) 9 (14.3)
Frequency of lower back pain:
On some days 4 (4.7) 4 (6.4)
On most days 13 (15.3) 12 (19.1)
Everyday 68 (80.0) 47 (74.6)
The length of time since free of low back pain for one whole month:
< 3 months ago 23 (27.4) 21 (33.3)
≥ 3 months ago but < 7 months ago 18 (21.4) 5 (7.9)
≥ 7 months ago but < 3 years ago 26 (31.0) 24 (38.1)
≥ 3 years ago 17 (20.2) 13 (20.6)
Pain down the leg:
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Table 2 Demographic and clinical characteristics of respondents at baseline (Continued)
Yes 62 (72.9) 46 (73.0)
No 23 (27.1) 17 (27.0)
If Yes:
Pain spread below the knee:
Yes 38 (62.3) 27 (58.7)
No 23 (37.7) 19 (41.3)
Roland Morris disability questionnaire (0–24, 0 = best)
No. of participants 85 63
Mean (SD) 10.66 5.9 10.6 5.3
Median (IQR) 11.0 (6.0, 14.0) 11.0 (6.0, 14.0)
Modified Von Korff disability score (0–100, 0 = best)
No. of participants 84 62
Mean (SD) 61.3 23.9 56.8 26.0
Median (IQR) 65.0 (48.3, 80.0) 58.3 (40.0, 76.7)
Modified Von Korff pain score (0–100, 0 = best)
No. of participants 84 63
Mean (SD) 68.5 20.3 67.1 17.2
Median (IQR) 73.3 (53.3, 83.3) 70.0 (56.7, 80.0)
Norm-based physical component score of SF-12 (0–100, 100 = best)
No. of participants 85 55
Mean (SD) 34.6 9.5 35.1 9.0
Median (IQR) 33.5 (27.2, 42.8) 34.3 (29.0, 40.0)
Norm-based mental component score of SF-12 (0–100, 100 = best)
No. of participants 85 55
Mean (SD) 42.6 12.8 44.4 12.2
Median (IQR) 42.7 (34.8, 53.6) 44.9 (37.2, 54.2)
Hospital anxiety and depression scale: anxiety (0–21, 0 = best)
No. of participants 83 60
Mean (SD) 7.6 4.4 7.5 4.2
Median (IQR) 7.0 (4.0, 11.0) 7 (4.5, 11.5)
Hospital anxiety and depression scale: depression (0–21, 0 = best)
No. of participants 82 59
Mean (SD) 7.2 4.7 7.2 5.0
Median (IQR) 6.5 (4.0, 10.0) 7 (3.0, 11.0)
Pain self-efficacy questionnaire (0–60, 60 = best)
No. of participants 82 61
Mean (SD) 34.2 15.6 31.5 14.8
Median (IQR) 37.0 (24.0, 44.0) 32.0 (19.0, 45.0)
Fear avoidance beliefs questionnaire (0–24, 0 = best)
No. of participants 85 59
Mean (SD) 14.3 5.9 15.5 5.5
Median (IQR) 15 (10.0, 18.0) 17 (12.0, 19.0)
Abbreviations: SD standard deviation; IQR interquartile range.
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Figure 1 CONSORT chart.
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similarly satisfied with their decision (Table 4).
The estimated cost of the decision support interven-
tion was £19.44 per person (comprising £2.20 for
consumables and £17.24 for physiotherapist training).
Participants’ use of NHS services for back pain and unit
costs for those health services were presented in Table 5
and Additional file 2: Table S1. Mean estimated costs for
other NHS services related to back pain over the trial
period in the intervention (n = 45) and control (n = 35)
arms were £245 and £271, respectively (mean difference£25.76, −116.54 to 168.05) (Additional file 3: Table S2).
Mean QALYs gained on the basis of EQ-5D data
(Table 6) over the four-month trial period were lower
for the decision support arm (n = 57) than usual care
(n = 38) arm: 0.18 and 0.22, respectively (mean difference
0.03, −0.01 to 0.07).
The regression-based estimates using imputed data
and adjusting for baseline differences between the
groups gave similar results: over four months, mean esti-
mated costs were £38 cheaper but mean estimated
QALYs were also 0.02 lower in the decision support arm
Table 3 Secondary outcome measures; number of
participants contributed to the analysis (first row), mean
change from baseline and difference between treatments
with 95% confidence interval
Mean change from baseline Mean treatment
difference*Decision support package Usual care
Roland Morris disability questionnaire (positive change = improvement)
n = 58 n = 40
1.9 (0.5 to 3.3) 4.2 (2.5 to 5.9) −2.27 (−4.47 to −0.08)
Modified Von Korff disability score (positive change = improvement)
n = 64 n = 49
17.1 (10.9 to 23.3) 18.2 (11.0 to 25.3) −1.07 (−10.50 to 8.37)
Modified Von Korff pain score (positive change = improvement)
n = 66 n = 50
14.7 (7.6 to 21.9) 24.0 (16.6 to 31.4) −9.24 (−19.44 to 0.96)
Norm-based physical component score of SF-12 (negative
change = improvement)
n = 53 n = 35
−5.5 (−7.7 to −3.3) −6.3 (−9.1 to −3.6) 0.80 (−2.71 to 4.32)
Norm-based mental component score of SF-12 (negative
change = improvement)
n = 53 n = 35
−3.4 (−6.4 to −0.4) −1.8 (−5.5 to 1.9) −1.64 (−6.36 to 3.09)
Hospital anxiety and depression scale: anxiety
(positive change = improvement)
n = 57 n = 36
0.5 (−0.5 to 1.5) 1.0 (−0.2 to 2.2) −0.46 (−2.01 to 1.09)
Hospital anxiety and depression scale: depression
(positive change = improvement)
n = 55 n = 36
1.1 (0.2 to 2.0) 2.2 (1.1 to 3.3) −1.12 (−2.52 to 0.28)
Pain self-efficacy questionnaire (negative change = improvement)
n = 57 n = 38
−4.6 (−9.4 to 0.2) −7.3 (−12.2 to −2.5) 2.74 (−4.04 to 9.51)
Fear avoidance beliefs questionnaire (positive change = improvement)
n = 56 n = 36
2.0 (0.2 to 3.9) 2.1 (−0.2 to 4.4) −0.09 (−3.04 to 2.87)
*Mean difference = (decision support package – usual care) after adjusting for
years of experience and pain severity at baseline as fixed effects and
physiotherapist as random effects; negative difference = favours usual care.
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tal cost effectiveness ratio of £1900 (£38/0.02) per QALY
gained for usual care compared with the decision sup-
port package, suggesting that the decision support inter-
vention would not be cost-effective. The extent of
uncertainty over the cost-effectiveness results is illus-
trated by the cost-effectiveness plane and the cost effect-
iveness acceptability curve (Figure 3 and Additional file
4: Figure S1). They show that the decision support pack-
age is unlikely to be cost-effective: with only 16%probability of being cost-effective at a threshold of
£20,000 per QALY gained. The expected value of perfect
information estimated from our base case is £30 per pa-
tient and £67 per patient when costs and QALYs are ex-
trapolated up to one year from baseline.
Discussion
Despite having a carefully designed decision support
package we have failed to show an improvement in satis-
faction with treatment. The striking finding here is that
for our primary outcome and for all but one of our sec-
ondary outcomes the direction of change is neutral or
favours the control arm. For one of these; the Roland
Morris Disability Questionnaire this difference appears
clinically important. The Roland Morris Disability Ques-
tionnaire is the leading primary outcome in community
based back pain studies [47]. The point estimate of the
dis-benefit from the decision support package at 2.3
points (95% CI 0.1 to 4.5) is larger than the effect size
found in the definitive trials supporting the use of the
back pain treatments included in the decision support
package. Previous back pain trials have reported a net
benefit on the Roland Morris Disability Questionnaire at
three months of 1.4 (95% CI 0.6 to 2.1) for an exercise
programme, 1.6 (95% CI 0.8 to 2.3) for a manipulation
package and 1.1 points, (0.37 to 1.74) for a group cogni-
tive behavioural approach [48,49]. This means that the
beneficial effects of physiotherapy treatment might be
negated by our decision support package.
One of the main strengths of this trial is the rigorous de-
sign of the intervention package; that has itself been sub-
ject to external peer review [32]. The intervention was
developed systematically using the International Patient
Decision Aid Standards Collaboration (IPDAS) framework
and its related checklist [50,51]. These cover best practice
in the development of decision support packages. The
training package for the physiotherapist was grounded in
principles from the Calgary-Cambridge Guidelines [52].
The training was designed and delivered by a Health
Psychologist (HS) with expertise in communication skills.
Some caution is needed in interpreting these data
because this is a pilot study run in one community
physiotherapy service thus the results may not be gener-
alisable. Nevertheless, the study was still adequately
powered to test the effect of our intervention on treat-
ment satisfaction. It is one of a very small number of tri-
als of decision aids that have collected patient reported
outcomes and the only trial, of which we are aware, to
have reported a cost-effectiveness analysis [13]. Some
caution is needed in interpreting the economic data be-
cause of the large amount of missing data. Nevertheless,
we have demonstrated that our intervention does not im-
prove satisfaction, it may produce worse clinical out-
comes, and that it is unlikely to be a cost-effective option.
Figure 2 Secondary outcomes; standardised mean difference with 95% confidence interval after adjusting for physiotherapist’s years
of experience and pain severity at baseline as fixed effects and physiotherapist as random effects.
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joining the department after the initial training compro-
mises our randomisation potentially leading to bias.
That the allocation of patients to physiotherapists was
managed by the department’s appointment staff blind to
randomisation gives some reassurance that the two
groups should have been well matched for unmeasured
confounders at baseline. Since new appointees tended toTable 4 Summary of satisfaction with decision
Decision support package Usual care
n/N (%) n/N (%)
Satisfied that I was adequately informed about the issues
important to treatment decision
Agreement* 45/58 (78) 37/45 (82)
The decision I made was the best decision possible for me personally
Agreement* 46/58 (79) 35/45 (78)
Satisfied that my decision was consistent with my personal values
Agreement* 47/57 (83) 36/44 (82)
Expect to successfully carry out (or continue to carry out) the
decision I made
Agreement* 48/58 (83) 37/43 (86)
Satisfied that this was my decision to make
Agreement* 46/58 (79) 34/43 (79)
Satisfied with my decision
Agreement* 47/58 (81) 35/43 (81)
*Agree, and strongly agree.be more inexperienced we judged that the direction of
any bias would be towards reducing any positive effect
size. In light of our results we did an additional post-hoc
sensitivity analysis, for the RMDQ, excluding partici-
pants treated by physiotherapists recruited after ran-
domisation. This showed the between group difference
in the RMDQ of 3.11 (95% CI 0.51 – 5.71). This does
not suggest that any bias introduced would substantially
affect our conclusions (Additional file 5: Table S3).
The 2011 Cochrane review of decision aids did not
identify any apparent adverse effects on health outcomes
or satisfaction in 86 trials of decision support [11]. The
authors did note the risk of bias from possible failure to
report negative outcomes in published studies. Our data
are not sufficient to conclude unequivocally that this deci-
sion support package is harmful. The harm identified
might reflect no more than random chance in a study with
multiple outcomes. Nevertheless, the overall trend across
our pool of outcomes is to favour the control intervention
and the harm identified was in a measure which would
have been likely to be chosen as a primary outcome in any
definitive trial. It would be difficult to justify a further ran-
domised trial to confirm our findings.
We hypothesise that this decision support package
introduced uncertainty about the overall effectiveness of
the available treatment options, both in terms of their
modest effect sizes and the weakness of the underpinning
evidence, thus reducing expectation of benefit. Our
promotion of evidence based practice and shared decision
making may have affected the therapist-patient
Table 5 Mean NHS service use: 0–4 months
Number of patients Mean quantity Mean treatment difference
(95% CI) (usual care - DSP)
DSP Usual care DSP (SD) Usual care (SD)
NHS Services
General Practitioner 57 39 1.4(2.1) 1.1(1.5) −0.28(−1.05 to 0 .50)
Practice nurse 58 39 0.1(0.4) 0.03(0.2) −0.08(−0.21 to 0.06)
Physiotherapist visit** 81 60 3.8(3.7) 3.1(3.7) 0.72(−1.97 to 0.52)
Doctor/nurse in an emergency department(casualty) 58 39 0.2(0.7) 0.1(0.3) −0.10 (−0.34 to 0.13)
Hospital specialist (consultant or team member) 58 39 0.1(0.5) 0.5(1.5) 0.42 (−0.00 to 0.84)
Psychologist/counsellor 58 39 0.03 (2.3) 0.1(0.5) 0.04 (−0.11 to 0.19)
Hospital stay 57 40 0.04(0.2) 0(0) −0.04(−0.09 to 0.02)
NHS Tests
X-rays 58 39 0.1(0.3) 0.0(0.2) 0.03(−0.14 to 0.07)
CT scan 58 39 0.02(0.1) 0.03(0.2) 0.01(−0.05 to 0.07)
MRI scan 57 39 0.1(0.3) 0.3(0.6) 0.16 (−0.04 to 0.36)
Blood tests 58 39 0.2(0.5) 0.1(0.3) 0.05 (−0.22 to 0.11)
NHS Drugs
Pain killers 57 39 1.2(2.0) 1.3(1.5) 0.08 (−0.67 to 0.83)
Anti-inflammatory drugs 58 39 0.8(1.3) 0.9(1.2) 0.08 (−0.43 to 0.58)
Gels/creams 58 39 0.2 (0.5) 0.1(0.2) 0.11(−0.28 to 0.07)
Sleeping pills 58 39 0.1(0.5) 0.1(0.4) 0.04 (−0.24 to 0.16)
Anti-depressants 58 39 0.2(0.7) 0.4(0.9) 0.17 (−0.16 to 0.50)
**Based on physiotherapist’s medical record.
Table 6 Utility weights and quality-adjusted life years estimates




DSP Usual care DSP Usual care
EQ-5D:
Baseline 84 61 0.4 (0.4) 0.5 (0.3) 0.01 (−0.10 to 0.12)
4 month 58 39 0.5 (0.4) 0.7 (0.3) 0.13 (−0.01 to 0.26)
Change from baseline to 4-month 57 38 0.1 (0.3) 0.2 (0.3) 0.05 (−0.05 to 0.16)
QALY gains (AUC 0–4 month) 57 38 0.2 (0.1) 0.2 (0.1) 0.03 (−0.01 to 0 .07)
SF-6D:
Baseline 85 59 0.6 (0.1) 0.6 (0.2) 0.02 (−0.03 to 0.06)
4 months 57 39 0.7 (0.2) 0.7 (0.2) 0.03 (−0.03 to 0.10)
Change from baseline to 4-month 57 37 0.1 (0.1) 0.1 (0.2) 0.03 (−0.03 to 0.08)
QALY gains (AUC baseline to 4-month) 57 37 0.2 (0.1) 0.2 (0.1) 0.01 (−0.01 to 0 .03)
EQ-VAS:
Baseline 83 60 54.7 (26.3) 59.0 (20.6) 4.35 (−3.72 to 12.42)
4 months 55 37 68.0 (22.6) 67.7 (18.3) −0.28 (−9.14 to 8.59)
Change from baseline to 4-month 54 36 9.0 (21.0) 8.1 (15.9) −0.98 (−9.16 to 7.20)
Abbreviations: DSP decision support package; SD standard deviation; CI confidence interval; QALY quality-adjusted life years; AUC area under the curve.











Figure 3 Cost effectiveness plane.
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or the patients’ confidence in the physiotherapist thus re-
ducing the therapeutic effectiveness of the encounter.
There is, for example, evidence that acupuncture is more
effective when delivered by an enthusiastic practitioner ra-
ther than a neutral or negative practitioner [53]. In this
trial we did not include a process evaluation that might
have shed light on these issues. Future trials of similar
tools should include such an evaluation.
Conclusion
Although our findings are specific to our approach to
improving choice of back pain treatments, our findings
may be of considerable importance more generally. The
way in which risk information is presented can influence
decisions made [54]. Our results add to the evidence
that it cannot be assumed that the provision of add-
itional information and support for patients to achieve
informed decisions is risk free. Before decision aids are
implemented they should be formally evaluated to en-
sure safety as well as efficacy and cost-effectiveness.
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